Expand to shield: IL-15 and in situ lymphocytic proliferation
- PMID: 33628626
- PMCID: PMC7889171
- DOI: 10.1080/2162402X.2021.1886726
Expand to shield: IL-15 and in situ lymphocytic proliferation
Abstract
The tumor microenvironment includes a complex network of cytokines and chemokines that contribute to shaping the intratumoral immune reaction. Understanding the mechanisms leading to immune-hot (Immunoscore-high) altered (excluded and immunosuppressed) and cold tumors are of critical importance for successful anti-cancer therapies. Two essential mechanisms are highlighted. Specific chemokines and adhesion molecules appeared to target and attract immune effector T cells to the tumor microenvironment and to specific regions within the tumor. These mechanisms are dependent upon intratumoral IL-15 expression. Decreased IL15 expression also affected the local proliferation of B and T lymphocytes. A comprehensive analysis revealed a major contribution of IL15 in shaping the tumor immune contexture. Thus, an in situ lymphocytic infiltration is mediated through chemokines and attraction inside or around the tumor microenvironment, and an IL15-mediated in situ lymphocytic proliferation, which expand the local pool of intratumoral cytotoxic CD8 T-cells are key determinants of the immune contexture. Increased IL15 expression and local proliferation of T-cells were associated with decreased risk of tumor recurrence and prolonged survival of cancer patients. These data provide further mechanisms to prioritize research and help in designing better therapeutic interventions.
Keywords: IL-15; T-cells; attraction; chemokine; chromosomal instability; colorectal cancer; immunity; immunoscore; prognosis; proliferation; survival; tumor microenvironment.
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Figures

Similar articles
-
Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients.Sci Transl Med. 2014 Mar 19;6(228):228ra37. doi: 10.1126/scitranslmed.3007240. Sci Transl Med. 2014. PMID: 24648340
-
Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.J Immunother Cancer. 2020 May;8(1):e000599. doi: 10.1136/jitc-2020-000599. J Immunother Cancer. 2020. PMID: 32461349 Free PMC article.
-
IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.Eur J Immunol. 2007 Jun;37(6):1678-90. doi: 10.1002/eji.200636329. Eur J Immunol. 2007. PMID: 17492620
-
Regulation of CTL Infiltration Within the Tumor Microenvironment.Adv Exp Med Biol. 2017;1036:33-49. doi: 10.1007/978-3-319-67577-0_3. Adv Exp Med Biol. 2017. PMID: 29275463 Review.
-
IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection.Oncoimmunology. 2020 Jul 9;9(1):1790716. doi: 10.1080/2162402X.2020.1790716. Oncoimmunology. 2020. PMID: 32934886 Free PMC article. Review.
Cited by
-
Specific transcriptional programs differentiate ICOS from CD28 costimulatory signaling in human Naïve CD4+ T cells.Front Immunol. 2022 Sep 5;13:915963. doi: 10.3389/fimmu.2022.915963. eCollection 2022. Front Immunol. 2022. PMID: 36131938 Free PMC article.
-
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.J Immunother Cancer. 2023 Oct;11(10):e007725. doi: 10.1136/jitc-2023-007725. J Immunother Cancer. 2023. PMID: 37907221 Free PMC article. Clinical Trial.
-
Adoptive cell therapies in thoracic malignancies.Cancer Immunol Immunother. 2022 Sep;71(9):2077-2098. doi: 10.1007/s00262-022-03142-3. Epub 2022 Feb 7. Cancer Immunol Immunother. 2022. PMID: 35129636 Free PMC article. Review.
-
Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response.Oncoimmunology. 2023 Aug 5;12(1):2243169. doi: 10.1080/2162402X.2023.2243169. eCollection 2023. Oncoimmunology. 2023. PMID: 37554310 Free PMC article. Review.
-
CD8+ CD226high T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery.Cell Mol Immunol. 2023 Apr;20(4):365-378. doi: 10.1038/s41423-023-00978-2. Epub 2023 Jan 30. Cell Mol Immunol. 2023. PMID: 36717657 Free PMC article.
References
-
- Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, Botti G, Marincola FM, Ciliberto G, Pages F, Ascierto PA, et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J Transl Med. 2016;14:273. doi:10.1186/s12967-016-1029-z. PMID: 27650038. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials